IP Library Granted Patent US 10,196,431
Granted Patent B2
US 10,196,431 · App. 15/803,472 · Granted Feb 5, 2019

Light-activated chimeric opsins and methods of using the same

Inventors: Karl Deisseroth (Stanford, CA); Ofer Yizhar (Palo Alto, CA); Lief Fenno (San Francisco, CA); Peter Hegemann (Falkensee, DE); Matthias Prigge (Berlin, DE)
Assignee: The Board of Trustees of the Leland Stanford Junior University
C07K14/405A01K67/0275A61N5/06C07K19/00C12N13/00G01N33/5058A01K2217/052A01K2227/105A01K2267/0393A61K38/00A61N2005/0663C07K2319/00C07K2319/60G01N2500/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,196,431
App. No.
15/803,472
Granted
Feb 5, 2019
Kind
B2
Abstract

Provided herein are compositions comprising light-activated chimeric proteins expressed on plasma membranes and methods of using the same to selectively depolarize excitatory or inhibitory neurons.

Claims (24)

1. A mammalian cell comprising a polynucleotide comprising a nucleotide sequence encoding a light-responsive chimeric polypeptide comprising, in order from N-terminus to C-terminus:

a) an amino acid sequence having at least 90% amino acid sequence identity to amino acids 1-163 of the ChR1 amino acid sequence set forth in SEQ ID NO:16; and

b) an amino acid sequence having at least 90% amino acid sequence identity to amino acids 120-300 of SEQ ID NO:17.

2. The mammalian cell of claim 1 , wherein the light-responsive chimeric polypeptide comprises a C-terminal trafficking signal.

3. The mammalian cell of claim 2 , wherein the trafficking signal comprises the amino acid sequence KSRITSEGEYIPLDQIDINV (SEQ ID NO:15).

4. The mammalian cell of claim 1 , wherein the nucleotide sequence is operably linked to a promoter.

5. The mammalian cell of claim 1 , wherein the light-responsive chimeric polypeptide comprises a Glu to Thr amino acid substitution at position 122 relative to the amino acid sequence set forth in SEQ ID NO:16.

6. The mammalian cell of claim 1 , wherein the light-responsive chimeric polypeptide comprises a Glu to Thr amino acid substitution at position 162 relative to the amino acid sequence set forth in SEQ ID NO:16.

7. The mammalian cell of claim 1 , wherein the light-responsive chimeric polypeptide comprises a Glu to Thr amino acid substitution at position 122 and a Glu to Thr amino acid substitution at position 162 relative to the amino acid sequence set forth in SEQ ID NO:16.

8. The mammalian cell of claim 1 , wherein the cell is a neuronal cell.

9. The mammalian cell of claim 1 , wherein the cell is a muscle cell.

10. The mammalian cell of claim 1 , wherein the cell is a stem cell.

11. The mammalian cell of claim 1 , wherein the cell is an excitatory neuronal cell.

12. The mammalian cell of claim 1 , wherein the cell is an inhibitory neuronal cell.

13. The mammalian cell of claim 1 , wherein the cell further comprises a second light-activated polypeptide present in the cell membrane.

14. The mammalian cell of claim 13 , wherein the second light-activated polypeptide comprises an amino acid sequence having at least 85% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NOs:11, 12, 13, or 14.

15. A method of depolarizing an excitatory or an inhibitory neuron, the method comprising exposing the neuron to light of a wavelength between about 540 nm to about 560 nm, wherein the neuron expresses in its cell membrane a light-responsive chimeric polypeptide comprising, in order from N-terminus to C-terminus:

a) an amino acid sequence having at least 90% amino acid sequence identity to amino acids 1-163 of the ChR1 amino acid sequence set forth in SEQ ID NO:16; and

b) an amino acid sequence having at least 90% amino acid sequence identity to amino acids 120-300 of SEQ ID NO:17.

16. The method of claim 15 , wherein the neuron is an excitatory neuron present in a microcircuit, and where the method further comprises expressing a second light-activated polypeptide in an inhibitory neuron, wherein the second light-activated polypeptide comprises an amino acid sequence having at least 85% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NOs:11, 12, 13, or 14, and wherein the inhibitory neuron is exposed to light of a second wavelength.

17. The method of claim 15 , wherein the excitatory neuron is present in the prefrontal cortex.

18. The method of claim 15 , wherein the excitatory neuron comprises a pyramidal neuron.

19. The method of claim 15 , wherein the inhibitory neuron is present in the prefrontal cortex.

20. The method of claim 15 , wherein the inhibitory neuron comprises a parvalbumin neuron.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2018
From: DEISSEROTH, KARL; YIZHAR, OFER; FENNO, LIEF; HEGEMANN, PETER; PRIGGE, MATTHIAS
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 045836/0957 →
Continuity (8)
Continuation 15147772 · May 5, 2016
Continuation 14862926 · Sep 23, 2015
Division 13875966 · May 2, 2013
Continuation PCTUS2011059276 · Nov 4, 2011
Provisional Application 61511912 · Jul 26, 2011
Provisional Application 61410736 · Nov 5, 2010
Provisional Application 61410744 · Nov 5, 2010
Related Publication 20180051058A1 · Feb 22, 2018
Cited By (3)
US 12,510,744 US 12,655,474 US 12,730,295